Vaccination Coverage and Awareness of Hepatitis B Virus Among Healthcare Students at a University in Cyprus

Zoe Roupa1, Maria Noula1, Evi Farazi2, Antonis Stylianides1, Christos Papaneophytou1

ABSTRACT

Introduction: The risk for healthcare students to get infected by transmitting infectious viruses, including hepatitis B virus (HBV), in a hospital setting is extremely high through exposure to blood and/or body secretions. Aim: The aim of this work was to evaluate both the vaccination history of healthcare students at a University in Cyprus and their serologic immunity against HBV. In addition, we assessed their knowledge and behaviors towards the transmission and prevention of hepatitis B (HB). Results: Total amount of 168 students participated in this study and more than 50% of them provided complete documentation of vaccination history against HBV. Antibodies levels \( \geq 10 \) mIU/mL to HB surface antigen (HBsAg) were detected for the 98.8% of healthcare students while 1.2% of the participants tested positive for HBsAg and antibodies to HB core antigen indicating chronic infection. Our study also revealed significant gaps in the knowledge of healthcare students on the efficiency of the vaccine against HBV and in terms of the HBV transmission. Conclusions: More information needs to be provided to healthcare students in Cyprus regarding HBV transmission and vaccination. In addition, there is a need for intervention to provide a safer workplace environment.

Keywords: Hepatitis B, Students Health Occupations, Awareness, Vaccination, Prevention.

1. INTRODUCTION

Hepatitis B virus (HBV) infection, affects the liver and is a serious global health issue as chronic infection with the virus is associated with the development of hepatocellular carcinoma (1). HBV infection is ranked as the 15th cause of death worldwide, resulting in 0.5 to 1.2 million deaths annually (2). It is estimated that, globally, over 2 billion people have been infected with HBV while more than 240 million people are chronic carriers of HBV (3). HBV is transmitted mainly through exposure to infected blood and other body fluids including vaginal secretions and semen (4) whereas is able to survive for a long time outside the body (5). Even though HBV has been also detected in tears, sweat, breast milk, saliva, sweat, and urine, there is not any evidence of transmission through exposure to these body fluids when blood is not present (6).

A safe and effective vaccine against HBV has been introduced in 1982 (7). Though WHO’s universal vaccination action, HB vaccine was widely used and had been extended to all infants in order to achieve protection against HBV infection (8). Usually, a single course of three doses of the vaccine is administered in different schedules (e.g., at 0, 1, and 6 months), whereas a booster dose is administrated in some cases (9). A recombinant HBsAg is used for vaccination against HBV, and a positive immune response to the vaccine is defined as the development of antibodies to HBsAg (anti-HBs) at a titer of >10 mIU/mL. The vaccination efficiency is evaluated 1 to 3 months after the administration of the third (or fourth) dose of the vaccine (8). Vaccination against HBV has been proven as an effective strategy for the prevention of infection with the virus and at reducing chronic infections in both children and adults, especially in high-risk groups including health-care professionals (10, 11).

During their clinical work course, healthcare students (especially nursing students) are at high risk of acquiring infectious diseases, as...
well as transmitting them to their patient and/or to their co-workers. The determination of the HB vaccination status among healthcare students is essential to protect their health and to plan health education programs. Thus, the aim of this study was to evaluate the serologic immunity against HBV as well as the awareness and knowledge regarding HBV infection of healthcare students at a University in Cyprus. Another aim of this study was to evaluate the reliability of the history of vaccination against HBV documented by their doctors or reported by participants, to identify susceptible healthcare students.

2. AIM
The aim of this study was to evaluate the serologic immunity against HBV as well as the awareness and knowledge regarding HBV infection of healthcare students at a University in Cyprus. Another aim of this study was to evaluate the reliability of the history of vaccination against HBV documented by their doctors or reported by participants, to identify susceptible healthcare students.

3. MATERIALS AND METHODS
3.1 Study population
The study was conducted from July 2016 to July 2017 at the University of Nicosia, Nicosia Cyprus. Overall, 168 healthcare students between 18 and 38 years of age (mean 23.6 ± 4.3) participated in the study. The information obtained from these students during personal interviews (after written informed consent was provided) included name, sex, date, and place of birth, nationality, place of residence marital status and whether there was a history of hepatitis virus infection. Vaccination history was abstracted from each student’s vaccination records when available. The Cyprus National Bioethics Committee approved the study protocol.

3.2 Assessing HBV awareness and knowledge
The questionnaire consisted of three parts and was delivered in the Greek language. The first section focused on the demographic background of the participants including their gender, nationality, date of birth, marital status, place of birth and residence. The second part asked about previous vaccination against HBV. The third part was composed of a set of nine questions exploring knowledge on HBV vaccination, HBV transmission modes and protective measures, their source of knowledge about HB and attitude towards people infected with HBV.

3.3 Serologic studies
Blood samples were obtained from consented students and subsequently, serum was recovered by centrifugation (2000g, 10 min, 4°C) and stored at -20°C. Measurements of antibodies against i) hepatitis B surface antigen (anti-HBs) and ii) hepatitis B core antigen (HBc) and of hepatitis surface antigen (HBsAg) were performed with the commercially available enzyme-linked immunosorbent assay (ELISA) monolisaTM kits (anti-HBs Ultra, anti-HBc PLUS and HBsAg Ultra, respectively) (Bio-Rad; catalog numb: 72566, 72315, and 72346, respectively). All assays were performed according to the manufacturers’ instructions. All reactions were directly monitored using a temperature-control microplate reader (Victor X3; Perkin-Elmer). The levels of anti-HBs were calculated using a standard curve using the anti-HBs standard calibrators (Bio-Rad). An anti-HBs level ≥10 mIU/mL was considered protective. The presence or absence of antibodies against HB core antigen (anti-HBc) and of the HBsAg was determined by comparing each sample the recorded absorbance with that of the calculated cut-off value. The cut-off value for the detection of anti-HBs and HBsAg in serum samples was calculated as the mean negative control (MNC) value and the MNC value plus 0.050, respectively. Samples with a signal/cutoff ratio of >1.0 were considered to be positive, and those with a signal/cutoff ratio of <0.9 were considered to be negative (12). Students found to be positive HBsAg were referred to Nicosia’s general hospital for further tests.

3.4. Statistical analysis
SPSS 23.0 for Window package (SPSS Inc. Chicago, USA) was used for data entry and analysis Tables showing the frequency of certain variables were created and the statistical significance of the variables analyzed was assessed using the w2 Pearson test using SPSS program. Quantitative anti-HBs levels are also presented as geometric mean concentrations (GMC). Anti-HBs levels were log-transformed and were compared by analysis of variance (ANOVA) (15). The level of statistical significance was set at p<0.05.

4. RESULTS
4.1 Demographic data
Out of 200 questionnaires sent out, 168 valid questionnaires were recovered (31.0% males, 69.0% females) giving a response rate of 84 %, while 87 (51.7%) provided complete documentation of vaccination history. The characteristics of the sample used in this study are summarized in Table 1. Nearly two-thirds (66.1 %) of participants who were aged 20–24 years while most of them (84.5%) were not married. In addition, most of the participants were Cypriots (85.1%) followed by Greek (9.5%) whereas only 5.4% were from other countries including (Russia, Philippines, Croatia, and Moldavia). The place of birth and residence of the participants are also summarized in Table 1.

4.2 Immunization level for hepatitis B virus
To achieve protection against HBV it is mandatory to have anti-HBs levels ≥10 mIU/mL whereas three doses of the vaccine are usually administered in order to achieve full protection. Overall, 72 of 168 (42.8%) participants did not provide any vaccination records regarding HBV while 9 provided vaccination records that were incomplete (the age at first vaccination and/or the number of doses were not recorded). The vaccination status against HBV of 87 (51.7 %) students provided complete documentation of vaccination history since childhood by age group of vaccination is summarized in Supplementary Table 1. The number of doses and the age of vaccination varies among the healthcare students of our study. The majority of the participants (48 individuals, 28.6%) received the first dose against HBV at 0-1 years of age, 16 (9.5%) received the first dose between 2 and 10 years of age, 17 (10.1%) received the first dose between 11- 20 years of age and the rest 10 participants received the first dose between 21 and 30 years of age. As far as dosage compliance, 20 participants (11.9%) of the participants received the full series (4 doses), 48 (28.6%) had had three
doses, 3 (1.8%) had had 2 doses and 21 (12.5%) had had only one dosage dose administrated.

Immunization with three doses of HBV vaccine was statistically different between male and female participants (17 [32.7%] of 52 male vs 31 [26.7%] of 116 females; \( p=0.043 \)) (Supplementary Figure 1). In contrast, immunization with the full series (4 doses) of HBV vaccine was significantly higher among female participants than among male participants (16 [13.8%] of 116 females vs 4 [7.7%] of 52 males; \( p=0.007 \)) (Supplementary Figure 1).

4.3. HBV serological markers

**Anti-HBs Levels**

In this study, blood samples from all participants were analyzed to assess their serologic immunity against HBV. Data on the levels of IgG antibody against HBsAg (anti-HBs) among 168 participants are illustrated in Table 2. Overall, 2

| Characteristic | Participants (No) | Anti-HBs GMC, mIU/mL | Anti-HBs \( \geq 10 \) mIU/mL No (%) | \( p \)-value |
|---------------|------------------|----------------------|-------------------------------------|-------------|
| Sex           |                  |                      |                                     | >0.05*      |
| Male          | 52               | 206.82               | 50 (96.1)                           |             |
| Female        | 116              | 288.54               | 116 (100)                           |             |
| Age of vaccination |                |                      |                                     | >0.05      |
| 0-1           | 48               | 116.47               | 48 (100)                            |             |
| 2-10          | 16               | 260.44               | 16 (100)                            |             |
| 11-20         | 17               | 558.50               | 17 (100)                            |             |
| 21-30         | 10               | 261.00               | 9 (90)                              |             |
| Unknown†      | 77               | 295.96               | 76 (98.7)                           |             |
| Number of Doses |                |                      |                                     | >0.05      |
| 1             | 21               | 250.23               | 20 (95.2)                           |             |
| 2             | 3                | 55.33                | 3 (100)                             |             |
| 3             | 48               | 231.56               | 48 (100)                            |             |
| 4             | 20               | 241.13               | 20 (100)                            |             |
| Unknown†      | 76               | 307.26               | 75 (98.7)                           |             |
| Anti-HBs level |                |                      |                                     | <0.001***  |
| <10           | 2                | 3.91                 |                                      |             |
| 10-99         | 52               | 41.21                |                                      |             |
| 100-999       | 64               | 321.28               |                                      |             |
| 1000-1999     | 37               | 1313.10              |                                      |             |
| >2000         | 13               | 2798.13              |                                      |             |

GMC: geometric mean concentration. *Missing or incomplete vaccination records, †Student's t-test, ‡Chi-square test

Table 2. Serum levels of antibody to Hepatitis B surface antibody (anti-HBs) of the 168 participants in correlation to the vaccination scheme

(5.8%) male (n=52) participants (one Cypriot and one Greek) had an anti-HBs level <10 mIU/mL while 116 of 116 female (100%) participants had an anti-HBs level \( \geq 10 \) mIU/mL. One of the two students that had anti-HBs level <10 mIU/mL, received only one dose of the vaccine while the other one had missing vaccination records. The GMC for male participants was slightly lower than that of female participants (206.82 vs 288.54 mIU/mL respectively; \( p>0.05 \)). Even though 112 (66.7 %) of the participants were shown to have antibody titers >100 mIU/mL, no correlation was found between the number of doses administrated and the levels of anti-HBs (Supplementary Figure 2).

We subsequently analyzed results from the 87 students that had records regarding the age-group of vaccination and as shown in Table 2, even though there were differences in the anti-HBs GMC level by group, these differences were not statistically significant (\( p>0.05 \)). Interestingly, similar anti-HBs GMC levels were detected between the 0-1 (n=16) and 21-30 (n=10) group. In addition, we analyzed results from 92 students that had records regarding the number of doses (Table 2). However, the anti-HBs GMC levels did not statistically differ between the students that had had 1 (n=1), 3 (n=48) or 4 (n=20) doses of HBV vaccine, but the group that had had only 2 doses of the vaccine had 4-6 times lower anti-HBs GMC compared with the other groups. It should be noted that this group consisted only of three participants; one of them had an anti-HB level equal to 15 mIU/mL and the other equal to 35 mIU/mL. The anti-HBs
Vaccination Coverage and Awareness of Hepatitis B Virus Among Healthcare Students at a University in Cyprus

GMC levels for students with unknown vaccination status was equal to 295 mIU/mL. Table 2 also summarizes the anti-HBs levels of study participants and as already mentioned only two students had anti-HBs levels <10 mIU/mL, and their GMC of anti-HBs was 3.91 mIU/mL.

Detection of anti-HBc and HBsAg
During the testing for the presence of HBV serological markers in blood samples, 66 participants were tested positive for anti-HBc indicating previous infection. In addition, two participants (both Cypriots), were tested positive for HBsAg, a serological evidence of acute or chronic HBV infection. The presence of anti-HBc in the blood samples of the two participants indicated a chronic HBV infection. One of these students had anti-HBs levels equal to 13.10 mIU/mL and received one dose of the vaccine while the second one had anti-HBs levels equal to 11.5 mIU/mL and did not provide any vaccination records. Usually, in chronic HBV infection patients have HBsAg in the blood circulation but not anti-HBs (14). However, the presence of HBsAg along with anti-HBs has been reported in many cases (15-19).

4.4 Basic knowledge about HBV transmission and prevention
HBV vaccine awareness
Basic knowledge about HBV transmission and prevention was assessed by questions focusing on protection, side effects, transmission, and prevention. In the begging, participants have been asked to answer questions regarding the

| Question | n | % |
|----------|---|---|
| Does the HBV vaccine protect you against HBV infection? |  |  |
| Yes | 150 | 89.3 |
| No | 8 | 4.8 |
| N.A.* | 10 | 6.0 |
| If you have answered YES in above question then at what percentage does it protect you? |  |  |
| 40-50 | 13 | 8.7 |
| 60-80 | 44 | 29.3 |
| 80-90 | 51 | 34.0 |
| 90-100 | 34 | 22.7 |
| N.A.* | 8 | 5.3 |
| Are there any side effects of HBV vaccine? |  |  |
| Yes | 83 | 49.4 |
| No | 73 | 43.5 |
| N.A.* | 12 | 7.1 |
| If you have answered YES, in the previous question then what types of side effects are there? |  |  |
| Transmission of diseases | 3 | 3.6 |
| Usual side effects | 70 | 84.3 |
| Other | 6 | 7.3 |
| N.A.* | 4 | 4.8 |

Table 3. Knowledge regarding HBV vaccine

| Question | n | % |
|----------|---|---|
| How is HBV spread? |  |  |
| Sexual contact (true) | 130 | 77 |
| From mother to child (true) | 84 | 50 |
| Contact with infected blood (true) | 123 | 73 |
| Breath (false) | 2 | 1 |
| Saliva (false) | 29 | 17 |
| Feces (false) | 21 | 13 |
| Insects (false) | 17 | 10 |
| Food (false) | 2 | 1 |
| Sweat (false) | 11 | 7 |
| W.C. (false) | 29 | 17 |
| Social life (false) | 6 | 4 |
| After an accident with a needle contaminated by HBV what you have to do in the case are not vaccinated |  |  |
| Vaccination | 26 | 15.5 |
| Injection with hyperimmune globulin γ | 42 | 25.0 |
| Report to supervisor | 62 | 36.9 |
| I do not know | 61 | 36.3 |

Table 4. Knowledge regarding the transmission of HBV
vaccine against HBV (Table 3). Overall, 150 (89.3%) students knew that HBV could be prevented through vaccination, but only 22.7% (34/150) of the participants were aware regarding the efficiency of the vaccine. In addition, 83 of 168 students (49.4%) replied that vaccination against HBV causes some side effects, including the common side effects of any vaccine (70/83), transmission of diseases (3/83) or other side effects (6/83), while 4 participants did not know if there are any side effects from vaccination.

HBV transmission knowledge

Subsequently, participants were asked to answer questions regarding HBV transmission (Table 4). The majority of students demonstrated an acceptable level of knowledge about HBV transmission. Sexual, perinatal, and blood transmission of HBV were recognized by 77%, 50% and 73% of students respectively; however, a small proportion (1-4%) of participants did not know that HBV is not transmitted by breath, food, sweat, and social life. Interestingly, most students knew that HBV is not transmitted by saliva, feces, toilet, and insects. When students were asked what they have to do if they accidentally were injured with a needle contaminated by HBV (and they are not vaccinated against HBV), only 36.9% replied that they have to report the accident to their supervisor while 36.3% replied that they do not know what they have to do. It should be noted that after accidental exposure to blood contaminated with HBV unvaccinated persons should receive immediately the first dose of the vaccine along with hepatitis B immune globulin (HBIg) (20).

General questions about HBV and attitude towards HBV carriers

In the last part of the questionnaire, students were asked to answer some general questions about HBV and general attitude towards patients with HB (Table 5). More than one-half of the participants (54.2%) obtain information about HBV from the nursing department of University of Nicosia, 29 (17.3%) from the Cyprus ministry of health, 7 (4.2%) from the Hospital infection control committee, 27 (16.1%) from the social media and 59 (35.1%) from their personal environment. Overall, 109 students (64.9%) believe that are well informed about HBV, 50 (29.8%) believe that their knowledge about HBV is insufficient while 9 did not give an answer.

Overall, 121 (72%) students reported that they believe that it is safe for nursing patients with HB while eight (4.8%), did not answer the question. 39 (23.2%) students replied that it is dangerous to treat HBV carriers while the majority of them (24/39) had some concerns about their personal safety. In addition, 9 replied that they are not well informed about the transmission of the disease, 15 reported that there are insufficient safety measures in hospital, while 4 replied that there is a high risk to contaminate other patients and/or medical staff. When students were asked where they believe that it is safe to hospitalize HBV carriers, 10.1% (17/168) and 45.8% (77/168) replied in specific
hospitals or in specific hospital wings respectively, 27.4% (46/168) in isolation wards, 11.5% (19/168) reported that is save to keep HBV carriers in common hospital wards, while 6% (10/168) replied that HBV patients should stay in their houses.

5. DISCUSSION

The risk of infection with HBV for HCW in their workplace (and it is higher during training), is extremely high due to their potential contact with infected body fluids, including blood or vaginal fluid (21). Administration of vaccine against HBV is the most common vaccination among HCWs in several countries, e.g., Greece, Turkey, and Austria (22). Unfortunately, in Cyprus, there aren't sufficient data on the immunization status and seroprevalence of antibodies to vaccine-preventable diseases, including HBV, among healthcare students and professionals, while a comprehensive vaccination program in healthcare students has not been implemented.

This study revealed several interesting findings of healthcare students' vaccination status against HBV and their awareness of HBV infection. Specifically, the vaccination coverage of 168 healthcare students was examined by determining the anti-HBs levels in blood serum samples. Results regarding records for vaccination against HBV are not satisfying; 48.2% of the students had incomplete vaccination status. Of those students, two had levels of antibody to HBsAg that were lower than 10 mIU/L. According to European recommendations, the protective cutoff level of anti-HBs antibodies was set at > 10 mIU/mL (10). In our study, 52 participants had anti-HBs levels from 10 to 99 mIU/ml (Table 2) and we advised them to receive a booster dose of vaccine against HBV. An interesting observation during our serological HBV markers examination was that the group of participants aged 11-20 years when they received their primary vaccine series had the highest protective antibody levels (anti-HBs >10 mIU/mL) compared with those aged <10 or >20 years at primary vaccination. It has previously demonstrated that children vaccinated through catch-up programs or young adults vaccinated for occupational safety reasons have a high probability of being protected for several years (>20) (11). A high percentage of participants had incomplete vaccination records, and therefore it was difficult to find a correlation between the anti-HBs levels and the number of doses. In addition, no correlation was detected between gender and anti-HBs levels.

During the HBV serological markers examination, 66 participants were tested positive for anti-HBc. In general, the total antibody to HBV core antigen rises approximately 2-3 months after exposure to HBV and is a marker of natural infection (23). Following primary infection with HB, IgM anti-HBc antibodies are produced and are present in the bloodstream for 4 to 6 months. During recovery, HBsAg is cleared and the long-lived IgG anti-HBc antibodies are produced and then antibodies to HBsAg (anti-HBs) are developed (24). In several cases, serum samples have been found positive for total anti-HBc, but negative for both anti-HBs and HBsAg, a phenomenon that is called "anti-HBc alone". This serological response is compatible with resolved, acute, HBV infection but might also signify occult HBV infection (25). In our study, of 66 students, tested positive to anti-HBc, 4 had anti-HBs levels from 50 to 99 mIU/mL while the rest 62 had anti-HBs levels > 100 mIU/mL, indicating resolved HBV infection and that students have developed immunity against HBV. Surprisingly during the HBV serological markers tests, the HBsAg was detected in blood serum samples of 2 participants, whereas total anti-HBc antibodies also detected, indicating a chronic HBV infection (26). These students were referred to Nicosia's general hospital for further tests.

Moreover, in this study, we examined the awareness of the healthcare students about HBV, its transmission modes as well as the behavior of participant towards people with HB. The majority (89.3%) of the participants were aware that HBV vaccine provides protection against HBV infection, however awareness may not reflect knowledge since only 20.2% replied that the vaccine provides (after administration of the three doses) > 90% protection to infants, children, and adults immunized before being exposed to the virus. This contradicts the results in the research of Yasobant et al. (27) which two thirds of the population in Gujarat was found to be unaware about Hepatitis B and its vaccine, as well as, the results of a research done in Mumbai that showed that only less than 5% of the participants stated that they were aware of the disease (28). In addition, only 45.5% replied that vaccine is safe and does not cause any side effects and that the HB vaccine is not only one of the most effective but also one of the safest vaccine ever developed while side-effect have rarely been reported (Saridi et al., 2011).

In this study, a misconception regarding the transmission modes of HBV was observed among the participants and only 12 of 168 replied that HBV is transmitted by unprotected sex, from mother to child during pregnancy and by contact with infected blood. A significant proportion (56.3%) of our participant replied that they do not know what they have to do if they get injured with a contaminated by-HBV needle (in the case they are not vaccinated) while only 62 (36.9%) participant replied that they have to report their supervisor.

Inadequate knowledge is probably an important factor in HBV infection. The majority of the participants believed that are well informed regarding HBV infection, while the most common source of HBV information reported by our participants was universities' nursing departments. Of our 168 participants, 121 replied that is safe to take care of people infected with HBV. On the other hand, while 39 believed that is not safe because they mainly worry about their personal safety, while 49 (of 168) participant replied that HB patients should be hospitalized in isolated wards.

Limitations of the Study

A limitation of the study was that almost 50% of the participants had incomplete vaccination records against HBV. Additionally, according to Loftin et al. (29) when students are used as participants in a study there is a high possibility of bias. Another limitation of our study was usage of a questionnaire that was not previously tested in a separate patient sample for reliability and validity; therefore results of the study should be interpreted with caution. However, the results are indicative of certain tendencies and could be considered as a pilot.
6. CONCLUSION

This study provides important information regarding vaccination status and serologic immunity against HBV among healthcare students in Cyprus and revealed that an urgent need to raise awareness and knowledge of HBV among healthcare students. HBV education should mainly focus on modes of transmission and precautions to avoid infecting others. In addition, to ensure the adequate protection of healthcare students, we propose blind immunization of students that have missing or incomplete vaccine records or selective vaccination after serologic evaluation of susceptibility.

- Declaration of patient consent: The authors certify that they have obtained all appropriate patient consent forms.
- Author contributions: All the authors contributed to the preparation of this paper: Z.R., M.N., and E.F. collected and managed data; A.S., E.F., and C.P. have performed final processing and analyzing of collected information and data; Z.R., A.S., and C.P. prepared the article for drafting or revising it critically for important intellectual content. All author gave final approval of the version to be published.
- Conflict of interest: The authors have declared that no conflict of interest exists.
- Financial support and sponsorship: This work was funded by internal finding from the University of Nicosia.

REFERENCES
1. Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology. 2009; 49(5 Suppl): S56-S60.
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 255 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012; 380(9859): 2095-2128.
3. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12): 2212-2219.
4. Papastergiou V, Lombardi R, MacDonald D, Tsotcharis EA. Global epidemiology of hepatitis B virus (HBV) infection. Curr Hepat Rep. 2015; 14(3): 171-178.
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3): 661-662.
6. Zheng Y, Lu Y, Ye Q, Xia Y, Zhou Y, Yao Q, et al. Should chronic hepatitis B mothers breastfeed? a meta analysis. BMC Public Health. 2011; 11: 502.
7. Lavanchy D. Viral hepatitis: global goals for vaccination. J Clin Virol. 2017; 55(4): 296-302.
8. FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Vaccine. 2015; 31(4): 584-590.
9. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006; 55(RR-16): 1-35.
10. Puro V, De Carli G, Cicalini S, Soldani F, Balslev U, Begovac J, et al. European recommendations for the management of healthcare workers occupationally exposed to hepatitis B virus and hepatitis C virus. Euro Surveill. 2005; 10(10): 260-264.
11. Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, et al. Antibody levels and protection after Hepatitis B Vaccination: Results of a 30-year follow-up study in response to a booster dose. J Infect Dis. 2016; 214(1): 16-22.
12. Ly TD, Servant-Delmas A, Bagot S, Gonzalez S, Férey M-P, Ebel A, et al. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol. 2006; 44(7): 2321-2326.
13. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009; 200(9): 1390-1396.
14. Zhang J-M, Xu Y, Wang X-Y, Yin Y-K, Wu X-H, Weng X-H, et al. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis. 2007; 44(9): 1161-1169.
15. Shiels MT, Tasweef HF, Cazaja AJ, Nelson C, Sweneke P. Frequency and significance of concurrent hepatitis B surface antigen and antibody in acute and chronic hepatitis B. Gastroenterology. 1997; 93(4): 675-680.
16. Kohno H, Inoue T, Tsuda F, Okamoto H, Akahane Y. Mutations in the envelope gene of hepatitis B virus variants co-occurring with antibody to surface antigen in sera from patients with chronic hepatitis B. J Gen Virol. 1996; 77: 1825-1831.
17. Lada O, Benhamou Y, Poynard T, Thibault V. Coexistence of hepatitis B surface antigen (HBsAg) and anti-HBs antibodies in chronic hepatitis B virus carriers: influence of “a” determinant variants. J Virol. 2006; 80(6): 2968-2975.
18. Mesenas SI, Chow WC, Zhao Y, Lim GK, Oon CI, Ng HS. Wild-type and ‘a’ epitope variants in chronic hepatitis B virus carriers positive for hepatitis B surface antigen and antibody. J Gastroenterol Hepatol. 2002; 17(2): 148-152.
19. Mathet VL, Feld M, Espinola L, Sanchez DO, Ruiz V, Mando O, et al. Hepatitis B virus S gene mutants in a patient with chronic active hepatitis B with circulating anti-HBs antibodies. J Med Virol. 2005; 69(1): 18-26.
20. Palmović D. Prevention of hepatitis B infection in health care workers after accidental exposure. J Infect. 1987; 15(3): 221-224.
21. Erhabor O, Ejele OA, Nwauche CA. Epidemiology and management of occupational exposure to blood borne viral infections in a resource poor setting: the case for availability of post exposure prophylaxis. Niger J Clin Pract. 2007; 10(2): 100-104.
22. Saridi M, Toska A, Soulitiotis K, N O, M S, Stamatiou K, et al. Vaccination coverage among healthcare workers in a Greek hospital. J Vaccines Vaccin. 2011; 2: 1-8.
23. Cavalieri SJ, Hrabovsky S, Jorgensen T. Comparison of Dia-Sorin and Bio-Rad test kits for the detection of Hepatitis B Virus total core and surface antibodies on the Bio-Rad evelos. Am J Clin Pathol. 2010; 135(1): 110-113.
24. Hourfar MK, Walch LA, Geusendam G, Dengler T, Janetzko K, Gubbe K, et al. Sensitivity and specificity of Anti-HBC screening assays--which assay is best for blood donor screening? Int J Lab Hematol. 2009; 31(6): 649-656.
25. Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. Lancet Gastroenterol Hepatol. 2017; 2(2): 125-134.
26. Krajden M, McNabb G, Petric M. The laboratory diagnosis of hepatitis B virus. Can J Infect Dis Med Microbiol. 2005; 16(2): 65-72.
27. Yasobant S, Trivedi P, Saxena D, Puwar T, Vora K, Patel M. Knowledge of hepatitis B among healthy population: A community-based survey from two districts of Gujarat, India. J Family Med Prim Care. 2017; 6(3): 589-594.
28. Jha S, Devaliya D, Bergson S, Desai S. Hepatitis B knowledge and attitude among women of childbearing age in three slums in Mumbai: a cross-sectional survey. Hepatol Med Policy. 2016; 1: 5.
29. Loftin C, Campanella H, Gilbert S. Ethical issues in nursing education: the dual-role researcher. Teach Learn Nurs. 2011; 6(3): 139-145.